logo-loader
viewAequus Pharmaceuticals Inc.

Aequus Pharmaceuticals has adequate funds and cash flow to operate business amid coronavirus outbreak

It continues to see prescriptions filled without interruption for both its PrVistitan treatment for glaucoma and Tacrolimus anti-organ rejection drug

Aequus Pharmaceuticals Inc. -
The firm has suspended in-field clinic and hospital visits for the time being

Aequus Pharmaceuticals Inc (CVE:AQS) (OTCMKTS:AQSZF) CEO Doug Janzen told investors that the firm has adequate funds and cash flow to operate the business amid the coronavirus outbreak.

In a statement, Janzen noted that the speciality pharmaceutical company's commercial products were taken daily to help manage serious chronic conditions.

READ: Aequus Pharmaceuticals welcomes Stu Fowler as strategic commercial advisor; Ian Ball transitions into Medicom role

He said the company continues to see prescriptions filled without interruption for both its PrVistitan (glaucoma) drug and Tacrolimus (anti-organ rejection) drug.

"To help ensure the continuity of our business operations, we have streamlined our responses to requests for product resources or samples and have been very active in ancillary initiatives such as digital marketing and targeting. Our partner, Sandoz, has confirmed that they are not having any manufacturing or supply issues with our partnered products," said Janzen.

"We have suspended in-field clinic and hospital visits for the time being, in an effort to both stay out of the way of essential services in our health care facilities as well as minimize the risk of exposure or inadvertent spreading of the virus by our employees. Our operational expenses have been significantly reduced during this period as a result," added the company boss.

Janzen said the group's launch efforts for the Evolve products continue and it would provide a separate update on launch timing and additional new products in coming weeks.

Shares in Toronto surged over 28% to C$0.090 each.

---Updates for share price---

Contact the author at [email protected]

Quick facts: Aequus Pharmaceuticals Inc.

Price: 0.1 CAD

TSX-V:AQS
Market: TSX-V
Market Cap: $8.04 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Aequus Pharmaceuticals Inc. named herein, including the promotion by the Company of Aequus Pharmaceuticals Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Aequus Pharmaceuticals acquires Canadian rights to therapies for Dry Eye

Aequus Pharmaceuticals (CVE:AQS-OTCQB-) Chairman and CEO Doug Janzen sat down with Steve Darling from Proactive Investors Vancouver to discuss the company acquiring the Canadian rights to a line of products that help people deal with Dry Eye. 

on 13/3/19

2 min read